Vascular calcifi cation is one of the most important factors for high morbidity and mortality from cardiovascular and cerebrovascular diseases. The aim of this study is to investigate the effect and mechanism of miR-26a on vascular smooth muscle cell calcifi cation. First, the VSMCs were induced by β-glycerol phosphate (β-GP) for 7d and 14d, and Al izarin Red S staining was performed to examine the mineralized nodule change; then re al time RT-PCR and western blotting were performed to explore the expression of mi R-26a, CTGF, OPG, RANKL and ALP in un-induced and β-GP-induced VSMCs; next, the VSMCs were transfected with miR-26a mimics, and Alizarin Red S staining was performed to examine the mineralized nodule change; fi nally, real time RT-PCR and western blotting were performed to explore the expression of miR -26a, CTG F, OPG, RANKL and ALP in un-tra nsfected and miR-26a mimics transfected VSMCs. After β-GP treatment, β-GP promoted clear mineralized nodule changes, and miR-26a a nd OPG expression were significantly decreased and CTGF, RANKL and ALP expression were increased in VSMCs. Overexpression of miR-26 a inhibited VSMCs calcifi cation induced by β-GP, and regulated the expression of CTGF, O PG, RANKL and ALP. Our fi ndings suggested that up-regulation of miR-26a before β-GP treatment inhibits VSMCs calcifi cation through targeting CTGF (Fig. 4, Ref. 18 ). Text in PDF www.elis.sk.
Introduction
Arterial calcifi cation refers to the pathological process of calciu m deposition in the arterial wall tissue. As a result, the arterial elasticity and hemodynamics decreased due to the deposition of calcium phosphate. It is common in diabetes, e nd-stage renal disease and in the elderly, and is an independent predictor of cardiovascular events ( 1) . According to the location of calcium salt depositions, arterial calcifi cation is divided into inner calcifi cation and middle ca lcifi cation. Calcifi cation can be induced by infl ammatory factors and lipids, and often coexist with atherosclerosis, which plays an important role in the occurrence of cardiovascular events. Medial calcifi cation can be present without atherosclerosis, may be induced by many factors such as hyperphosphatemia, hypercalcinemiac, uraemia, vascular dementia (VD), and is common in cardiovascular events, end-stage renal disease and diabetes (2, 3) .
There are many similarities between the process of arterial calcifi cation and bone formation, which are the processes of active regulation. Epidemiological studies have also suggested that there is a relationship between vascular calcifi cation and bone metabolism disorders. Vascular smooth muscle cells (VSMCs) tr ansdi fferentiation to osteoblast-like cells is the cytological basis and key link of the middle artery calcifi cation.
By microarray analysis, microRNA-26a can regulate osteoclast formation induced by RANKL and the target gene is connective tissue growth factor (CTGF) (4) . Other tar gets include regulating osteogenic differentiation of adipose tissue-derived stem cells modulated by the SMAD1 transcription factor (5), promoting muscle synthesis by regulating Ezh2 (6) . Many studies have shown that CTGF plays an important role in the process of tissue fi brosis and wound repair, which is the downstream molecule secreted by TGF-β1-activated cells. Overexpression of CTGF stimulates vascular smooth muscle cell growth and migration in vitro, to express more extracellular matrix proteins such as collagen type I and fi bronectin (7) . CTGF promotes osteoclastogenesis induced by RANKL (8) . However, the role o f miRNA-26a in the regulation of vascular calcifi cation in CTGF is u nknown.
In this study, we identified that β-GP induces calcifi cation of VSMCs, and examined the CTGF, OPG, RANKL and ALP expression levels and functional role of miR-26a in VSMCs.
Material and methods

Cell culture and treatment
Vascular smooth muscle cells (VSMCs) were obtained from the American Type Culture Collection (ATCC, USA) and grown in 
Alizarin Red S staining
For A lizarin Red S staining, the treated ce lls were incubated with 95 % ethyl alcohol for 1h at room temperature, then incubated with 1% Alizarin Red S solution (Sigma-Aldrich) for 30 min at 37 °C. The stain ing results of mineralized nodules were observed under microscope.
Real-time PCR (RT-PCR)
Real-time PCR was performed as previously described (9) . The primers were as follows: CTGF -forward 5'-CAG CAT GGA CGT TCG TCT G -3' and reverse 5'-AAC CAC GGT TTG GTC CTT GG -3'; OPG -forward 5 '-GCG CTC GTG TTT CTG GAC A -3' and reverse 5'-AGT ATA GAC ACT CGT CAC TGG TG -3'; RANKL -forward 5'-CAA CAT ATC GTT GGA TCA CAG CA -3' and reverse 5'-GAC AGA CTC ACT TTA TGG GAA CC -3'; ALP -forward 5 '-ACT GGG GCC TGA GAT ACC C-3' and reverse 5'-TCG TGT TGC ACT GGT TAA AGC -3';GAPDH -forward 5'-CGG AGT CAA CGG ATT TGG TCG TAT-3' and reverse 5'-AGC CTT CTC CAT GGT G GT GAA GAC-3'.
Western blotti ng
Western blottin g was performed as previously described (9). The following primary antibodies were used: human monoclonal anti-CTGF, anti-OPG, anti-RANKL, anti-ALP and anti-GAPDH (1:1000; Santa C ruz Biotechnology, USA).
Statistical analysis
All data are expressed as mean ± SD. Statistical analysis was performed using SPSS software version 19.0 (SPSS, IBM Corporation, Armonk, NY USA). The Student's t-test and ANOVA were used for the statistical analysis. p < 0.05 was considered as signifi cant diff erence.
Results
β-GP induces ca lcifi cation of VSMCs
To characterize the effects of β -GP in inducing calcifi cation of VSMCs, we assessed mineralized nodule changes after 7d and 14d. The results of Ali zarin Red S staining showed that β-GP promoted clear mineralized nodule changes (Fig. 1) . These results indicate that β-GP induces calcium deposition in VSMCs.
β-GP affects miR-26 a, CTGF, OPG, R ANKL and ALP expression
To clarify the mechanism s underlying the effects of β-GP in VSMCs, we measured miR-26a, CTGF, OPG, RANKL and ALP expression by RT-PCR and western blotting. The results of RT-PCR showed that β-GP promoted the expression of CTGF, RANKL and ALP mRNA, b ut inhibited the expression of miR-26a and OPG mRNA (p < 0.05 7d, p < 0.00 1 14d) ( Fig. 2A) . And the results of western blotting showed that the levels of CTGF, RANKL and ALP protein were increased signifi cantly, but the levels of miR-26a and OPG protein were decreased (p < 0.05 7d, p < 0.001 14d) (Fig. 2B) . These results indicate that β-GP induces calcifi cation of VSMCs.
MiR-26a inhibits VSMCs calcifi ca tion indu ced b y β-GP
To deter mine the effects of miR-26a on VSMCs calcifi c ation induced by β-GP, we transfected VSMCs with miR-26a mimics and control oligo, and then as sessed mineralized nodule changes. The results of Alizarin Red S staining showed that β-GP inhibits clear mineralized nodule changes (Fig. 3) . These results indicate that miR-26a inhibits calcium deposition in VSMCs induced by β-GP.
MiR-26a regulates CTGF, OPG , RANKL and ALP expressions in VSMCs induced by β-GP
To fur ther elucidate the mechanisms underlying the effects of miR-26a in VSMCs induced by β-GP was determined by RT-PCR and western blotting. T he results of RT-PCR showed that transient overexpression of miR-26a reduced the expression levels of CTGF and RANKL mRNA, but promo ted the expression of OPG mRNA (p < 0. 05) (Fig. 4A) . And the results of western blo tting showed that the levels of CTGF and RANKL protein were decreased significantly, but the level of OPG protein was increased (p < 0.0 5) (Fig.  4B) . No signifi cant difference in the expression of ALP protein was observed. These results indicate that transient overexpression of miR-26a decreased the calcifi cation of VSMCs induced by β-GP.
Discussion
Vascular calcifi cation is a co mmon pathological manifestation of atherosclerosis, hypertension, diabetic vascular disease, vascular injury, chronic kidney disease and aging, mainly manifested as increased vascular wall stiffness, decreased compliance, myocardial ischemia, left ventricular hypertrophy and heart failure, leading to thrombosis and plaque rupture. Cardiovascular calcifi cation is directly associated with increased cardiovascular and global morbi dity and mortality. It represents an important part of the CKD-MBD (chronic kidney disease-mineral and bone disorders) complex and is a superior predictor of clinical outcomes in our patients (1, 10) . Many recent studies have shown that high phosphate induces VSMCs ca lcifi cation (11, 12) . I n this study, VSMCs were treated with β-GP, high phosphorus induced VSMCs trans-differentiation to osteoblast-like cells.
OPG/RANKL/RANK system is one of the important pathways to regulate bone metabolism. OPG (osteoprotegerin) is a member of the TNF-receptor superfamily, and an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. RANKL (Receptor Activator for Nuc lear Factor-κB Ligand), also known as TNF-related activation-induced cytokine (TRANCE), encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. CTGF is a mitogen that is secreted by vascular endothelial cells, which is one of the target genes of RANKL (4, 8, (13) (14) (15) (16) . ALP is an alkaline phosphatase, a metalloenzyme that catalyzes the hydrolysis of phosphoric acid monoesters.
MicroRNAs (miRNA) are a class of non-coding single-stranded RNA molecules of about 22 nucleotides encoded by endogenous genes. They are involved in the regulation of a wide range of physiological processes. In recent years, many studies have shown that microRNAs play important roles in bone metabolism and vascular calcifi cation. MiR-125b and miR-204 regulate transdifferentiat ion and calcifi cation of vascular smooth muscle cells in a high-phosphate environment (12, 17) . MiR-26a regulates extrac ellular matrix homeostasis in cartilage and RANKL-induced osteoclast formation (4, 18) . In our study, VSMCs were transfected with miR-26a mimics, and then induced by β-GP. The results of Alizarin Red S staini ng displayed that miR-26a inhibits the calcifi cat ion of β-GP-induced VSMCs. The results of RT-PCR and western b lotting have shown that miR-26a promotes the level of OPG and inhibits the levels of CTGF and RANKL. Accordingly, we presume the possible mechanism involved is that overexpres- sion of miR-26a may restore the calcifi cation of vascular smooth muscle cell calcifi cation induced by high phosphorus.
In summary, we provide novel evidence that miR-26a is an important mediator which contributes to β-GP-induced calcifi cation of VSMCs, providing a new target for therapeutic intervention of the diseases related to cardiovascular calcifi cation.
